L5K5W peptide

L5K5W peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

KKLLKWLKKLL

Lys-Lys-Leu-Leu-Lys-Trp-Leu-Lys-Lys-Leu-Leu

11

96.3%

Synthetic

Powder

A prototype de novo design of amphipathic helix involves Lys and Leu residues (LK-peptides). Studies indicate that 14-15 such residues are required to form a helical peptide active against bacteria. Shorter peptides are inactive, while longer peptides tend to be hemolytic. This 11mer peptide becomes active after inserting Trp, a membrane anchor. KL-peptide K6L9, seq LKLLKKLLKKLLKLL-NH2, consists of a mixture of L, D-amino acids. L5K5W displays antimicrobial activity and was identified in de novo design.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Kang SJ, Won HS, Choi WS, Lee BJ. De novo generation of antimicrobial LK peptides with a single tryptophan at the critical amphipathic interface. J Pept Sci. 2009;15(9):583-8.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.